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ABSTRACT
Retroviruses favor target-DNA (tDNA) distortion and
particular bases at sites of integration, but the
mechanism underlying HIV-1 selectivity is
unknown. Crystal structures revealed a network of
prototype foamy virus (PFV) integrase residues that
distort tDNA: Ala188 and Arg329 interact with tDNA
bases, while Arg362 contacts the phosphodiester
backbone. HIV-1 integrase residues Ser119,
Arg231, and Lys258 were identified here as analogs
of PFV integrase residues Ala188, Arg329 and
Arg362, respectively. Thirteen integrase mutations
were analyzed for effects on integrase activity
in vitro and during virus infection, yielding a total of
1610 unique HIV-1 integration sites. Purine (R)/pyr-
imidine (Y) dinucleotide sequence analysis revealed
HIV-1 prefers the tDNA signature (0)RYXRY(4), which
accordingly favors overlapping flexible dinucleotides
at the center of the integration site. Consistent with
roles for Arg231 and Lys258 in sequence specific
and non-specific binding, respectively, the R231E
mutation altered integration site nucleotide prefer-
ences while K258E had no effect. S119A and S119T
integrase mutations significantly altered base pref-
erences at positions  3 and 7 from the site of viral
DNA joining. The S119A preference moreover
mimicked wild-type PFV selectivity at these pos-
itions. We conclude that HIV-1 IN residue Ser119
and PFV IN residue Ala188 contact analogous tDNA
bases to effect virus integration.
INTRODUCTION
Retroviral integrase (IN) enzymes catalyze the insertion of
reverse-transcribed viral DNA (vDNA) into host chromo-
somal or target DNA (tDNA) as an essential step toward
productive virus infection. The multistep integration
process initiates with the formation of the stable
synaptic complex or intasome, which is comprised of an
IN tetramer and the two ends of linear vDNA (1–3). IN
processes the vDNA ends adjacent to conserved CA
sequences, which liberates a pGTOH dinucleotide from
each 30-end of HIV-1 DNA (4,5). The target capture
complex (TCC) subsequently forms in the nucleus when
the intasome engages tDNA (3). IN catalyzes the con-
certed joining of the CAOH ends to the 50-phosphates of
a staggered double stranded cut in tDNA (3,6,7). Repair
of the single-stranded gaps at the vDNA–tDNA junctions
yields the ﬂanking duplication of the tDNA cut sequence,
which varies from 4 to 6bp among integrated retroviruses.
Although integration can occur throughout most of the
animal cell genome (8), it is not random (9,10). There are
seven retroviral genera (a through e, lenti and spuma), and
the different viruses differentially target chromatin
features during integration. Lentiviruses such as HIV-1
prefer the bodies of active genes within gene-dense
regions of chromosomes (11), whereas Moloney murine
leukemia virus (MLV), a prototypical g-retrovirus,
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factors dictate these targeting preferences: bromodomain
and extraterminal domain (BET) proteins were shown
recently to mediate promoter proximal integration by
MLV (13–15), while lens epithelium-derived growth
factor (LEDGF)/p75 in large part dictates the lentiviral
preference for active genes (16–18). Retroviruses also
prefer particular nucleotides at sites of integration as
evident by weakly conserved palindromic sequences that
center on the tDNA cut (9,19–21). Integration site nucleo-
tide preferences of lentiviruses are notably independent of
cellular LEDGF/p75 content (17,18).
The X-ray crystal structure of the prototype foamy
virus (PFV) TCC revealed that the intasome accommo-
dates tDNA in a severely bent conformation (7). As
predicted by the relatively weak nature of palindrome con-
servation at sites of retroviral integration, the majority of
IN–tDNA contacts in the TCC were mediated through the
phosphodiester backbone (7). IN is comprised of separate
protein domains that include the N-terminal domain,
catalytic core domain (CCD) and C-terminal domain
(CTD) (22), and main chain amide groups of several
CCD residues as well as the side chain of CTD residue
Arg362 mediated interactions with the tDNA backbone.
The side chains of two key PFV IN amino acids, Ala188
and Arg329, in contrast made contacts with tDNA bases.
Consequently, recombinant Ala188 and Arg329 IN
mutant proteins displayed DNA-strand-transfer defects
and selected for novel nucleotide preferences at sites of
PFV integration in vitro (7). Based on these observations,
we hypothesized that HIV-1 IN amino acids that interact
with tDNA bases could be identiﬁed by comparing
integration sites of mutant IN enzymes to the canonical
integration sequence (–3)TDG#(G/V)TWA(C/B)CHA(7)
(written using standard International Union of
Biochemistry base codes; the vertical arrow marks the
position of vDNA plus-strand joining and the underline
highlights the tDNA duplication, which is 5bp for HIV-1)
(20,21). Structure-based IN amino acid sequence align-
ments were perused to identify HIV-1 IN amino acids
analogous to PFV IN residues Ala188, Arg329 and
Arg362, and 13 mutations targeting these as well as
nearby residues were tested for their effects on IN
enzyme function, HIV-1 infection and nucleotide site pref-
erences at sites of integration in vitro and in virally
infected cells.
MATERIALS AND METHODS
Plasmids and protein puriﬁcation
Hexahistidine (His6)-tagged HIV-1HXB2 IN was expressed
in bacteria from pCPH6P-HIV1-IN (23). LEDGF/p75
was expressed in bacteria using pFT-1-LEDGF, which
also yields N-terminal His6-tagged protein (24). The
single-round HIV-luciferase (Luc) reporter construct was
pNLX.Luc(R-)AvrII (25) whereas pCG-VSV-G was
used to express vesicular stomatitis virus G (VSV-G)
glycoprotein (17). Mutations introduced by PCR using
Pfu Ultra DNA polymerase (Agilent Technologies, Inc.)
were veriﬁed by DNA sequencing. Plasmid pGEM-3 or
pGEM9zf(-) served as tDNA in in vitro concerted integra-
tion reactions (23,26).
IN and LEDGF/p75 were expressed and puriﬁed from
bacteria essentially as previously described (24,27) and the
His6 tags were removed by proteolysis with human rhino-
virus 3C protease (GE Healthcare). Puriﬁed MuA
transposase protein was a kind gift from Dr Michiyo
Mizuuchi, National Institute of Diabetes and Digestive
and Kidney Diseases, National Institutes of Health
(NIH).
IN activity assays and integration product sequencing
In vitro assays for quantiﬁcation of Mg
2+-dependent
HIV-1 IN 30-processing, DNA-strand transfer and con-
certed integration activities were performed as previously
described (26–28). Concerted vDNA strand transfer
reaction products were isolated, sub-cloned and sequenced
essentially as previously reported (7).
Cells, viruses and infections
HEK293T and SupT1 cells were propagated in Dulbecco’s
modiﬁed Eagle medium and RPMI 1640 (Gibco—Life
Technologies), respectively, supplemented to contain
10% fetal bovine serum, 100IU/ml penicillin and 100mg/
ml streptomycin. HEK293T cells were co-transfected with
pNLX.Luc(R-)AvrII and pCG-VSV-G at the mass ratio
of 10:1 to produce single-round HIV-Luc pseudotypes.
Viral production was monitored using a p24 antigen
capture immunoassay (ABL, Inc.), and SupT1 cells
(4 10
5) were infected with 5ng/ml p24 of wild-type
(WT) or IN mutant virus in triplicate in 96-well plates.
Luc values, expressed as percent WT relative light units,
were determined 48h post-infection.
Viral integration site cloning
SupT1 cells (5 10
6) in 6-well plates were spinoculated
with WT or mutant virus preparations at 150ng/ml p24
for 2h, incubated for an additional 4h and then washed,
resuspended in 75cm
2 ﬂasks and cultured for 48h. DNA
was extracted with the DNeasy Blood and Tissue Kit
(Qiagen), and integration sites were ampliﬁed using
either restriction enzyme digestion (17) or bacteriophage
Mu transposition-based (29) protocols essentially
as described previously. Genomic DNA was digested at
37 C overnight with 100 U each of AvrII, SpeI and NheI,
puriﬁed with the QIAquick PCR Puriﬁcation Kit (Qiagen)
and ligated to a double-stranded linker consisting
of AE5237 (50-[PO4
=]CTAGGCAGCCCG[AmC7-Q])
and AE5238 (50-GTAATACGACTCACTATAGGGCA
CGCGTGGTCGACGGCCCGGGCTGC) (30). The
DNA was PCR-ampliﬁed using primers AE5239 (50-GA
GGGATCTCTAGTTACCAGAGTCACA) and AE5240
(50-GACTCACTATAGGGCACGCGT), diluted 1:200,
and subjected to a second PCR round using primers
AE5241 (50-AGCCAGAGAGCTCCCAGGCTCAGATC)
and AE5242 (50-GTCGACGGCCCGGGCTGCCTA).
Alternatively, annealed Mu right-end adaptors
AE4455 (50-GTAATACGACTCACTATAGGGCTCCGC
TTAAGGGACTGTTTTCGCATTTATCGTGAAACGC
TTTCGCGTTTTTCGTGCGCCGCTTCA) and AE4456
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GCGTTTCACGATAAATGCGAAAACA[AmC7-Q])
were incubated with MuA transposase (440ng) and 250ng
XhoI-digested genomic DNA at 30 C for 2h in buffer
(12.5ml) containing 25.8mM Tris–HCl, pH 8.0, 68mM
NaCl, 1mg/ml bovine serum albumin, 10mM MgCl2,
0.08mM EDTA, 0.05% Triton X-100 and 15% glycerol.
The DNA (2ml) was PCR-ampliﬁed using AE4392 (50-GTA
ATACGACTCACTATAGGGC) and AE4395 (50-GCAC
CATCCAAAGGTCAGTGGATATCTG), diluted as
above, and re-ampliﬁed using AE4393 (50-AGGGCTCCG
CTTAAGGGAC) and AE4394 (50-GTGTGTGGTAGAT
CCACAGATCAAGG). Puriﬁed second round PCR
products (500ng) from both protocols were incubated
with 10ng pCR4-TOPO (Life Technologies) for 30min,
followed by transformation of competent Top10 bacteria.
Individual colonies seeded in 96-well plates in LB medium
containing 100mg/ml kanamycin were sequenced at
Beckman Coulter using the T3 reverse primer or viral
U3-speciﬁc AE4396 (50-CCACAGATCAAGGATATCTT
GTC).
Quantitative PCR analysis of vDNA
SupT1 cells (1 10
6/well of a 12-well plate) were
spinoculated with 100ng/ml p24 of DNase-treated virus
for 2h. Cells were washed and reseeded into 48-well plates
at 2.5 10
5 cells/well. The concentration of cellular DNA
extracted at 8, 24 and 48h post-infection using the
DNeasy Blood and Tissue Kit was measured by spectro-
photometry, and normalized DNA levels were analyzed
by quantitative PCR (qPCR). Primers and probes for
quantiﬁcation of late reverse transcription (LRT)
products and integrated proviruses were as described
(31). Plasmid pNLX.Luc(R-)AvrII diluted in uninfected
genomic DNA generated the LRT standard curve,
whereas dilutions of DNA recovered from cells infected
for 48h with HIV-Luc served as the integration standard
curve. DNA was prepared from parallel infections con-
ducted in the presence of 10mM efavirenz (NIH AIDS
Research and Reference Reagent Program) to account
for residual transfected plasmid DNA in the qPCRs,
and these background values, which varied from 0.4 to
1.3%, were subtracted from experimental samples.
Bioinformatic analysis of integration sites
Sample sizes required for statistically signiﬁcant compari-
sons between the WT and random, or between WT and
mutant IN-integration-site sequences, were calculated
using a Cohen’s d value of 0.8, desired statistical power
level of 0.9, and probability level or P-value of 0.05 (32),
which yielded 34 as the minimal number of unique sites
needed.
Data derived from infected cells was processed as
described (11,17) to remove all U3, linker- and vector-
derived sequences, duplicate sequences and sequences
that did not contain the processed 50-TTAGCCCTT
CCA U3 terminus. Matches to human DNA were
identiﬁed using BLAT (UCSC Human Genome Project,
February 2009 GRCh37/hg19 assembly) and judged
acceptable if they contained >98% average identity over
the entire length of the sequence and also yielded a unique
best hit in BLAT ranking. Positions  5 to 4 were experi-
mentally determined, while positions 5–9 were assumed
from genomic sequences upstream of the mapped
integration site.
Consensus nucleotide sequences were visualized using
the WebLogo program (33). Differences in integration
sites from random, which was calculated relative to the
pGEM9zf(-) plasmid sequence for in vitro integration
site analysis and relative to 10000 computer-generated
sites for cellular DNA analysis, were determined by chi-
square as described (17,34). Nucleotide preferences of IN
mutants were also compared to the WT sequences using
chi-square analysis.
Purine (R)/pyrimidine (Y) dinucleotide content was
calculated by counting the number of the four kinds of
sequences (RY, YR, RR and YY) in bins of dinucleotides
from positions  10 to 14; IN mutant analyses were
conﬁned to the same windows as the nucleotide analyses
(dinucleotide bins  5 to 8). Dinucleotide frequencies were
normalized to the total number of WT or IN mutant
integration sequences and also to the dinucleotide
content of pGEM-9Zf(-), which was calculated as 23.9%
RY, 23.9% YR and 52.2% RR/YY from 10
6 computer-
generated integration sites. WT HIV-1 IN dinucleotide
frequency was compared to these randomly generated
in silico integration sites using chi square analysis, and
the dinucleotide preferences of IN mutants were
compared to the WT also using chi-square analysis.
RESULTS
Experimental strategy
The X-ray crystal structure of the PFV TCC revealed a
network of protein–tDNA interactions mediated through
IN main chain and side chain atoms. The subset of IN
CCD residues that contacted tDNA through polypeptide
backbone amides (7) were not considered here due to
potential complications of interpreting the effects of side
chain substitutions on the function of main chain protein
atoms.
Previous structure-based PFV/HIV-1 amino acid
sequence alignments (2,27) were analyzed to identify po-
tential functional analogs of PFV IN residues Ala188,
Arg329 and Arg362. Ala188 forms part of the short
CCD a2 helix that additionally harbors Ala189, Phe190
and Thr191 (Figure 1A). Phe and Thr are conserved in the
analogous HIV-1 IN a2 helix, where residues Ser119 and
Asn120 align with PFV IN residues Ala188 and Ala189,
respectively. Ser119 and Asn120 were accordingly targeted
for mutagenesis. Although the CTD is the least conserved
domain among retroviral IN proteins (22), Arg362 aligned
with HIV-1 IN residue Lys258 at the same relative
position within CTD b4 (Figure 1B). Arg329 forms part
of the loop that connects CTD b1 and b2 strands, which is
four residues longer in PFV IN than the analogous loop in
HIV-1 IN (2,27) (Figure 1B). Although HIV-1 IN residue
Arg231 could be aligned with Arg329, adjacent residues
Asp229, Ser230 and Asn232 were additionally targeted
due to potential ambiguity in this region of the sequence
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a bacterial expression vector to assess effects on recom-
binant HIV-1 IN enzyme activity and integration site
sequence preferences in vitro: S119A, S119T, N120A,
N120E, D229R, S230N, R231E, R231H, R231Q, R231S,
N232R, K258E and K258S.
Biochemical activities of recombinant IN proteins
His6-tagged IN proteins were puriﬁed from bacterial
extracts using Ni
2+-nitrilotriacetate chromatography,
and the His6 tag was removed by site-speciﬁc proteolysis
prior to IN activity assays. IN 30-processing and DNA-
strand-transfer activities were initially analyzed using
relatively short (21 and 30bp, respectively) mimics of the
viral U5 end. The blunt ended 30-processing substrate was
labeled at the internal phosphate of the pGTOH dinucleo-
tide to afford quantitation of 30-processing activity
independent from DNA strand transfer activity, and the
DNA-strand-transfer substrate was pre-processed to allow
this activity to be analyzed independent of 30-processing
activity (Figure 2A). Separate 30-bp molecules serve as
vDNA and tDNA substrates under these strand transfer
reaction conditions (35).
IN containing the D64A active-site mutation was
expressed and puriﬁed for use as a negative control in
enzyme activity assays (27). Because the proﬁle of
K258S IN mutant 30-processing and DNA-strand-
transfer activities mirrored those of D64A IN, K258S
IN was at best minimally active (Figure 2B). In contrast,
S119T IN supported the WT level of the IN 30-processing
and DNA-strand-transfer activities. Whereas numerous
additional INs, including S119A, N120A, N120E,
S230N, R231E, R231H, R231Q and R231S, also
supported the WT level of 30-processing activity, each
mutant displayed between a 20% and 80% reduction in
DNA-strand-transfer activity. Both the 30-processing and
DNA-strand-transfer activities of N232R IN were reduced
 2-fold from the WT, whereas mutants D229R and
K258E were more defective, supporting between  5 and
25% of the levels of WT IN activity (Figure 2B).
Sequence analysis of in vitro integration products
We next sought to determine tDNA nucleotide preferences
for the mutant enzymes that supported appreciable levels
of IN-strand-transfer activity. Although the prior
sequencing-gel-based assay supports strand-transfer
activity, the relatively short tDNA oligonucleotide
provides a suboptimal degree of sequence heterogeneity
to query all four nucleotides at multiple positions of
vDNA joining. We accordingly included supercoiled
plasmid DNA as an integration target in the reaction
mixture, which additionally distinguishes products that
form through the integration of a single vDNA end
from those that form by the concerted integration of
two vDNA ends. For reasons that are not entirely clear,
HIV-1 IN preferentially integrates single oligonucleotide
vDNAs into tDNA, which yields nicked plasmid circles
that co-migrate through agarose gels with open circular
plasmids isolated from Escherichia coli. Concerted integra-
tion of two vDNA ends by contrast yields linear plasmid
DNA products (Figure 3A). The system therefore affords
analysis of concerted integration reaction products that
harbor proper 5-bp tDNA duplications (28,36,37). As
we previously established that the addition of LEDGF/
p75 protein signiﬁcantly enhanced the concerted integra-
tion activity of HIV-1 IN in vitro (28), mutant IN activities
were compared to the WT in both the presence and
absence of the integration cofactor.
In the absence of LEDGF/p75, WT IN displayed a
basal level of half-site integration activity (Figure 3A,
compare lanes 2 to 1). As expected (28), LEDGF/p75
boosted the formation of half-site and concerted vDNA
Figure 2. HIV-1 IN 30-processing and DNA-strand-transfer substrate
design and enzyme activities. (A) Substrate cartoons are shown to high-
light the different U5 DNA+strand termini and positions of radiolabel
(*). The vertical arrow and underline in the 30-processing substrate
mark the scissile phosphodiester bond and cleaved pGTOH dinucleo-
tide, respectively. (B) IN mutant 30-processing (black) and strand-
transfer (gray) activities expressed as percentages of WT IN function.
Results are averages±standard deviation (SD) for three experimental
replicates. Paired analyses revealed mutant activities that differed sig-
niﬁcantly from the WT (*P<0.05; **P<0.01) as well as individual
mutant IN strand-transfer activities that differed signiﬁcantly from
the level of 30-processing activity (asterisks above brackets).
Figure 1. PFV and HIV-1 IN sequence alignments. (A) Structure-based
amino acid sequence alignment of IN CCDs with secondary elements
(a and b represent a helix and b strand, respectively) noted atop the
sequences. PFV assignments (upper) are from protein database (PDB)
code 3OY9, whereas the HIV-1 elements (lower) are from reference
(27). (B) Sequence alignment of IN CTDs. PFV IN residues Ala188,
Arg329 and Arg362 in panels (A) and (B) are highlighted in yellow and
underlined. HIV-1 IN residues targeted for mutagenesis are underlined
and highlighted in red. Positions of amino acid identity are marked by
asterisk, while colons mark positions of chemical similarity.
Nucleic Acids Research,2014, Vol.42, No. 8 5167integration products signiﬁcantly (compare lanes 3 to 2).
Similar to the WT enzyme, the formation of IN mutant
concerted integration products was LEDGF/p75-depend-
ent (Figure 3A). Relative levels of IN mutant concerted
integration activities in large part mirrored the DNA-
strand-transfer activity levels observed in the sequencing
gel-based assay (compare Figure 3B to Figure 2B, grey
bars).
LEDGF/p75-dependent integration reactions were
scaled up 30- to 90-fold (for the minimally active K258E
mutant), and linear DNA products isolated from agarose
gels were ligated to a kanamycin resistance cassette as
previously described (7). Due to their relatively low
levels of strand transfer activity (Figures 2 and 3), IN
mutants D229R and K258S were omitted from this
analysis. Plasmids isolated from individual bacterial
colonies that released an insert of expected size upon
restriction enzyme digestion were subjected to dideoxy
sequencing using primers that faced outward from the
kanamycin cassette. The total number of sequences that
contained two vDNA ends varied from a low of 60 for
K258E IN to a high of 170 for the R231S mutant
(Table 1). About 83% of the WT sequences harbored
5-bp duplications, while  9% and 7% harbored deletions
or duplications other than 5bp, respectively (Table 1).
Most of the mutant enzymes yielded 5-bp duplications
at frequencies similar to the WT, with notable exceptions
of S119A and S119T INs. The frequencies of 5-bp
duplications for these enzymes hovered  60%, with con-
comitant increases in the number of product DNAs that
harbored deletions and aberrant duplications of plasmid
sequences (Table 1).
Site preferences were tabulated from concerted vDNA
integration products that contained unique 5-bp duplica-
tions, which included 1090 WT and IN mutant sequences
(Table 1). Observed nucleotides were compared to the fre-
quency expected at each position based on the sequence of
the tDNA plasmid, and P-values were calculated by  
2-
analysis. Our dataset recapitulated the preference of WT
IN for TDG#(G/V)TWA(C/B)CHA, with the observed
frequency at each nucleotide position differing signiﬁcantly
from random (Figure 4 and Supplementary Figure S1). The
integration sites of the mutant enzymes were additionally
compared to the base preference of the WT enzyme at each
position. Each mutant that contained an alteration of a
CCD a2 residue notably displayed a novel tDNA
sequence preference (Figure 4 and Supplementary Figure
S1). S119A and S119T IN each selected for novel
Figure 3. Concerted vDNA integration activities of HIV-1 IN proteins. (A) The agarose gel image highlights migration positions of the pre-pro-
cessed 32-bp vDNA substrate, supercoiled (s.c.) and open circular (o.c.) forms of pGEM-3 tDNA, as well as products of half-site and concerted
vDNA integration. The reactions loaded in lanes 1 and 18 omitted IN protein; LEDGF/p75 was included in each set of reactions as indicated.
(B) Results (average±SD for n=3 experiments) of HIV-1 IN mutant concerted integration activities normalized to WT, which was set at 100%.
Asterisks highlight signiﬁcant differences from the WT as deﬁned in Figure 2.
5168 Nucleic Acids Research, 2014,Vol.42, No. 8nucleotides at position 7: S119A IN preferred cytosine over
adenosine (P =2 . 5  10
 8) whereas S119T IN preferred
thymidine with a bias against guanosine (P=1.3 
10
 10). Compared to the WT, S119A IN additionally
favored adenosine and disfavored cytosine at position 6
(P=1.6 10
 4). N120A IN revealed a bias for thymidine
at position 6 (P=0.003), while N120E IN displayed a
marginal preference for guanosine at position 4
(P=0.04). Two of the mutant enzymes with changes in
the loop region between CTD b1a n db2, R231E and
R231H, also displayed modest preferences for guanosine
at position 4 (P-value differences of 0.013 and 0.04 versus
the WT, respectively). In contrast, the nucleotide sequence
preferences of S230N, R231Q, R231S, N232R and K258E
INs did not differ signiﬁcantly from the WT (Figure 4 and
Supplementary Figure S1).
The X-ray structure of the PFV TCC demonstrated that
tDNA is severely bent to accommodate the scissile
phosphodiester bonds at the IN active sites. This distor-
tion is enabled by the unstacking of the two central base
pairs at positions 1 and 2 from the site of vDNA joining
(7). Pyrimidine (Y)-purine (R) dinucleotides display lower
base-stacking properties than RR and YY, or the most
rigid RY dinucleotide (38), and YR dinucleotides are
accordingly favored at positions 1 and 2 during PFV
integration (7). PFV integration yields a 4-bp duplication
of tDNA sequences (39). Because HIV-1 integration yields
5-bp duplications, we reasoned the mechanism of tDNA
bending might very well differ from that of PFV. The 25
nucleotides that span positions  10 to 14 of the WT HIV-
1-integration sites were grouped into 24 dinucleotide bins
(Figure 5A and B). The frequencies of RR and YY
dinucleotides generally hovered around the combined
random average of 52.2% (calculated from one million
computer-generated integration sites), with points of
signiﬁcant difference at bins  2 and 5. Greater frequency
alterations were however noted for the rigid RY signature
at bins 0 and 3 surrounding the central base pair at the site
of integration. Thus,  47% of the bin 0 and bin 3
dinucleotides were RY, practically doubling the unbiased
frequency of 23.9% (Figure 5B; replotted as fractional RY
usage in panel C). Concomitantly, a signiﬁcant decrease to
 5% of the most ﬂexible YR dinucleotide was observed at
these positions. RY and YR dinucleotide frequencies
settled toward the random 23.9% value further away
from the site of integration. Bin 0 and bin 3 RY
dinucleotides notably increase the frequency of ﬂexible
YR dinucleotides at nucleotide positions 1 and 2 and at
positions 2 and 3, as the (0)RYXRY(4) signature gives rise
to either YR or YY nucleotides at positions 1 and 2, which
translates to either RR or YR dinucleotides at positions
2 and 3.
Analysis of IN mutant protein fractional RY signatures
revealed similar preferences for RYXRY at the integra-
tion site, with the notable exception of the R231H mutant
(Supplementary Figure S2). In this case the frequency of
RY at bin positions 0 and 3 was actually lower than the
frequencies observed at other positions (bins  5,  1, 4
and 8; Supplementary Figure S2A). One other Arg231
mutant protein, R231Q, also revealed a signiﬁcant ﬂuctu-
ation from the WT signature, with a novel switch in pref-
erence for RY sequences at bin positions  2 and 5 outside
of the central RYXRY motif. The N120A mutation, like
R231H, signiﬁcantly reduced the frequency of RY at
central bin positions 0 and 3, yet in this case the bin 0
and 3 RY frequency remained greatest across the integra-
tion site (Supplementary Figure S2B). IN mutant S119A
yielded the largest alterations from the WT, in this case
signiﬁcantly increasing the RY frequency at bins  3 and 6
(Supplementary Figure S2C). The marked preferences for
GT at nucleotide positions  3 and  2 and for AC at
positions 6 and 7, respectively (Figure 4), account for
this unique signature. The other IN mutant proteins did
not reveal signiﬁcant RY frequency differences from WT
IN (Supplementary Figure S2).
Infectivities and DNA analyses of HIV-1 IN
mutant viruses
SupT1 cells were infected with normalized amounts of
single-round WT and IN mutant viruses that carried and
expressed the Luc reporter gene. Two days post-infection,
cells were harvested and mutant viral Luc activities were
calculated as percentage of WT activity. As the K258S
mutation abrogated IN activity under all assay conditions
in vitro, it was omitted from the virus study. Each tested
mutation signiﬁcantly reduced HIV-1 infectivity, with the
extent of the infection defect ranging from  25% for the
S119A IN mutant virus to >100-fold for the N120E and
K258E mutant viruses (Figure 6).
Integration site sequences were determined for the WT
virus and ﬁve mutant viruses (S119A/T, N120A and
Table 1. WT and IN mutant in vitro integration products
IN Concerted integration products Five-bp duplication (%) Unique 5-bp duplication (%) Deletions (%) Other duplications (%)
WT 163 136 (83.4) 122 (74.8) 15 (9.2) 12 (7.4)
S119A 168 97 (57.7) 92 (54.8) 44 (26.2) 27 (16.1)
S119T 159 94 (59.1) 87 (54.7) 40 (25.2) 25 (15.7)
N120A 168 149 (88.7) 131 (77.9) 8 (4.8) 11 (6.5)
N120E 163 131 (80.4) 120 (73.6) 15 (9.2) 17 (10.4)
S230N 86 70 (81.4) 65 (75.6) 4 (4.7) 12 (14.0)
R231S 170 131 (77.1) 119 (70.0) 23 (13.5) 16 (9.4)
R231E 129 124 (96.1) 112 (86.8) 2 (1.6) 3 (2.3)
R231Q 82 66 (80.5) 65 (79.3) 7 (8.5) 9 (11.0)
R231H 80 69 (86.3) 66 (82.3) 7 (8.6) 4 (5.0)
N232R 83 64 (77.1) 62 (74.7) 7 (8.4) 12 (14.5)
K258E 60 58 (92.1) 49 (77.8) 0 (0) 2 (3.3)
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5170 Nucleic Acids Research, 2014,Vol.42, No. 8R231H/S) that supported at least 10% of the levels of WT
infectivity and integration (Figure 6 and Supplementary
Figure S3). Genomic DNA from infected cells was
digested with restriction endonucleases and ligated to
asymmetric linkers or utilized as a template for in vitro
bacteriophage Mu transposition as described (17,29).
The modiﬁed DNAs were then ampliﬁed by two rounds
of PCR, cloned and sequenced. Duplicated sequences as
well as sequences that did not match the processed U3 end
of vDNA, cellular genome and linker DNAs at >98%
identity were omitted from the analysis. Cellular se-
quences upstream from the point of U3 vDNA joining
were compiled from the draft human genome. In total,
520 unique integration sites were determined for the six
viruses. Observed nucleotides at the sites of vDNA joining
were compared to those expected based on the sequence of
Figure 5. Dinucleotide content analysis of WT HIV-1 IN in vitro concerted integration sites. (A) Dinucleotide bin positions are deﬁned using the
WebLogo consensus sequence for WT HIV-1 IN from the upper left panel in Figure 4 as guide. (B) Frequencies of RY and YR (left y-axis)
and RR and YY content (right y-axis) at and surrounding the integration sites. (C) Graph showing the frequency of rigid versus ﬂexible dinucleotides
(% RY/(YR+YY/RR)) for WT HIV-1 IN across the integration site. The dashed lines (B) indicate the expected frequency of RY and YR (23.9%) or
RR/YY (52.2%) dinucleotides and (C) the expected RY/(YR+YY/RR) frequency (31.4%). P-values (B) reﬂect the signiﬁcance of the change in
dinucleotide preference of WT HIV-1 IN versus randomly generated sequences and (C) signiﬁcance of the change in preference of rigid dinucleotides
over ﬂexible dinucleotides. *P 0.05; **P 0.005.
Nucleic Acids Research,2014, Vol.42, No. 8 5171human DNA, which was calculated from 10000
computer-generated coordinates.
Although our results in large part recapitulated the WT
preference for the TDG#(G/V)TWA(C/B)CHA consen-
sus sequence, we noted lack of palindromic symmetry
among the virus-derived integration sites (Figure 7 and
Supplementary Figure S4). Viral integration datasets in
the vast majority of cases are derived from cellular se-
quences that abut one of the two integrated vDNA ends,
and the inclusion of events that generated duplications
other than 5bp or deletions during integration will skew
palindrome symmetry. Despite this limitation, the muta-
tions that altered the preferences of puriﬁed IN enzymes
in vitro imparted similar novel nucleotide preferences
during HIV-1 infection. Accordingly, the S119A mutant
virus disfavored adenosine and preferred cytosine at
position 7 (P=7.9 10
 4), with recognizable alterations
in complementary T/G utilization at position  3. Though
the viral data failed to recapitulate the statistically signiﬁ-
cant preference for G/T bases at position  2 that was
observed in vitro, this trend was nevertheless evident.
The S119A IN mutant virus also disfavored guanosine
at position 9 and favored adenosine at position 0. The
S119T IN mutant virus behaved quite similar to its
puriﬁed enzyme counterpart, in that similar novel base
preferences were selected at positions  3 and 7
(compare Figures 4 and 7). The N120A mutant virus
revealed marginal preferences for adenosine and cytosine
at positions 0 and 3, respectively. The Arg231 mutant
viruses also yielded nucleotide preference patterns
similar to those observed with mutant enzymes in vitro.
Compared to the WT, the R231H mutant preferred ad-
enosine and guanosine at positions 0 and 4, respectively,
as well as guanosine at position 7. The R231S IN mutant
viral integration preference in large part mirrored the WT
pattern, with a marginal shift at position 4 toward
unbiased frequencies of A/C utilization (P=0.02;
Supplementary Figure S4).
DISCUSSION
The crystal structure of the PFV TCC revealed unprece-
dented details on the mechanism of retroviral DNA integra-
tion (7). Two inner monomers of an IN tetramer interact
with both vDNA and tDNA and donate the active sites
required to integrate the vDNA ends. The intasome accom-
modates tDNA in a severely bent conformation, which is
accomplished by the enzyme wrenching down on a prefer-
entially bendable substrate. The unstacking of the two base
pairs at the center of the integration site is accordingly
facilitated by the marked preference for ﬂexible YR di-
nucleotides. IN CCD and CTD residues furthermore
contact the tDNA at numerous positions outside this
central base pair: the amide groups of numerous CCD
residues as well as the Arg362 side chain interact with the
tDNA backbone, whereas Ala188 and Arg329 make base-
speciﬁc contacts (7). HIV-1 IN residues Ser119, Arg231 and
Lys258 were identiﬁed here as analogues of PFV IN residues
Ala188, Arg329 and Arg362, respectively (Figure 1). WT
and IN mutant enzyme activities and nucleotide site prefer-
ences in vitro and in virus-infected cells were analyzed to
assess amino acid residue roles in tDNA recognition
during HIV-1 integration.
The role of CCD a2 residues in tDNA binding and HIV-1
integration
Retroviral IN amino acid analogs of PFV IN residues
Ala188 and Ala189 have previously been implicated in
tDNA recognition, primarily through novel banding
patterns of DNA-strand-transfer reaction products in
sequencing gels (41–44). Our results ﬁne-tune the
analysis by narrowing which tDNA bases are likely con-
tacted by HIV-1 IN residue Ser119 during integration.
The methyl group of PFV IN residue Ala188 mediates a
van der Waals interaction with the O2 atom of cytosine 6,
and PFV accordingly favors cytosine and guanosine at
positions 6 and  3, respectively, during integration (7).
PFV IN mutant A188S by contrast favored adenosine
and thymidine at positions 6 and  3, respectively
(Supplementary Figure S5). HIV-1 IN, which harbors
Ser at the position analogous to Ala188 in PFV IN, ac-
cordingly favors adenosine and thymidine at nucleotide
positions 7 and  3, respectively (positions 5–7 in the
HIV-1 integration site are analogous to positions 4–6 in
the PFV site due to the 5- and 4-bp tDNA cuts made by
HIV-1 and PFV IN, respectively). Moreover, HIV-1 IN
mutant S119A favored cytosine and guanosine at pos-
itions 7 and  3, respectively (Figure 4), in a sense
recapitulating the WT PFV IN preferences at these
positions (Supplementary Figure S5). Based on these
observations, we conjecture that Ser119 in HIV-1 IN
and Ala188 in PFV IN interact with tDNA similarly
during vDNA integration. Accordingly, the methyl
group of the HIV-1 IN mutant S119A side chain might
preferentially form a van der Waals interaction with
cytosine at position 7 during integration. Consistent with
this hypothesis, rhesus macaque simian immunodeﬁciency
virus, which harbors alanine at the analogous position in
IN (45), favors cytosine at position 7 (21). Rous sarcoma
virus (RSV), an a-retrovirus that produces a 6-bp
Figure 6. Single-cycle HIV-1 infections. The infectivity of each
indicated IN mutant virus is normalized to the level of WT virus in-
fection, which was set to 100%. Results are average±SD for two
independent experiments, each performed in duplicate. Asterisks
denote statistically relevant differences from the WT (*P<0.05;
**P<0.01; ***P<10
 4). Residue 232, which is a known polymorphic
site in IN (40), is Asn and Asp in our HIV-1HXB2-based bacterial and
HIV-1NL4-3-based viral expression vectors, respectively.
5172 Nucleic Acids Research, 2014,Vol.42, No. 8target-site duplication, harbors serine at the analogous IN
position 124 (43) and favors adenosine at position 8 of its
consensus integration site (21). Furthermore, the lentivirus
equine infectious anemia virus (EIAV), which carries
threonine at this position in IN (45), reveals remarkable
preference for thymidine and adenosine at position 7
(18,46), virtually identical to the selectivity of our HIV-1
S119T IN mutant (Supplementary Figure S5). It seems
unmistakable that this position in IN is dedicated to inter-
acting with the bases that lay three residues of either side
of the tDNA cut.
The conservation of a compact amino acid at positions
analogous to Ala188 in PFV IN is likely important for
tDNA recognition across retroviral INs (7). Accordingly,
introducing bulky electronegative aspartate or glutamate
residues for Ser124 in RSV IN abrogated mutant enzyme
strand-transfer activity (47). It is unclear whether Asn120
in HIV-1 IN might interact directly with tDNA, or
whether the relatively modest novel preferences for
nucleotides at sites of N120E and N120A IN mutant
integration are due to indirect effects on the neighboring
Ser119 side chain. A search of the Los Alamos HIV
Sequence Database revealed that Asn120 is completely
conserved across HIV-1/SIVcpz strains (48). In contrast,
proline, which predominates at Ser119 analogous pos-
itions across retroviral IN proteins (45), is oftentimes
found in HIV-1/SIVcpz IN.
The HIV-1 IN CTD and tDNA binding
Arg329 in PFV IN hydrogen bonded with tDNA bases
guanine 3, guanine  1, and thymine  2 in the TCC
crystal structure, while Arg362 interacted with the
tDNA backbone. The R329E mutation in PFV IN
severely reduced DNA-strand-transfer activity, and the
mutant integration sites revealed a signiﬁcant novel pref-
erence for cytosine at position  1 (7). R231E and K258E
substitutions in HIV-1 IN also yielded signiﬁcant reduc-
tions in DNA strand transfer activity (Figures 2 and 3).
R231E IN displayed novel preferences for A/C and T/G at
positions 0 and 4, respectively, whereas K258E IN did not
select for signiﬁcant nucleotide differences from the WT
integration sequence (Figure 4 and Supplementary Figure
S1). These results are consistent with our hypothesis from
structure-based sequence alignment that Arg231 and
Lys258 in HIV-1 IN mediate tDNA base and backbone
contacts, respectively. While the R231E mutant enzyme
retained the WT level of 30-processing activity, K258E
IN displayed  3 fold 30-processing defect (Figure 2).
Although the signiﬁcant further reduction in K258E IN
DNA-strand-transfer activity is consistent with a role for
Lys258 in tDNA binding, the associated 30-processing
defect suggests that Lys258 might play more than one
role in HIV-1 integration. The K258A IN mutation (49)
like K258E (Figure 6) reduced HIV-1 single-round infect-
ivity >100-fold.
The isolated HIV-1 IN CTD binds DNA non-speciﬁc-
ally (50–53), and exposure of the Arg231 side chain on a
saddle-shaped groove in an NMR structure of a CTD
dimer originally implicated this residue in tDNA binding
(54). While our results are consistent with a role for
Arg231 in tDNA binding, the absence of an analogous
dimer in the PFV IN-DNA co-crystal structures has
since questioned the biological relevance of the isolated
CTD multimeric form (2,7).
Figure 7. Integration site preferences of WT and IN mutant viruses. The legend to Figure 4 explains the heights of the different base logos within a
stack and the heights of the different stacks along the x-axis. Asterisks denote statistically signiﬁcant differences from the WT signature at the
indicated nucleotide position (*P<0.05; **P<0.01; ***P<10
 5).
Nucleic Acids Research,2014, Vol.42, No. 8 5173Although a subset of Arg231 mutants selected for novel
integration site preferences in vitro and in cells (Figures 4
and 7), the magnitude of these effects are signiﬁcantly less
than the preference of PFV IN mutant R329E for cytosine
at position  1 (7). Different possibilities were considered
to account for this outcome. First and foremost, the
HIV-1 IN CTD may not possess a single residue that is
functionally analogous to Arg329 in PFV IN, which
imparts signiﬁcant distortion through contacting
multiple nucleotides that surround a central, ﬂexible YR
dinucleotide. Our dinucleotide analysis revealed a marked
preference for RYXRY by HIV-1 (Figure 5), which
enforces ﬂexibility at the two dinucleotide positions that
overlap the central base pair. Thus, the inherent asymmet-
ric ﬂexibility instilled through selective YY or YR nucleo-
tides at positions 1 and 2 and concurrent YR or RR
nucleotides at positions 2 and 3 may very well necessitate
an asymmetric recognition mechanism through more than
one IN amino acid residue. It seems possible that a single
HIV-1 IN residue may also be unable to span sufﬁcient
distance to contact numerous nucleotides that are minim-
ally separated by an additional base pair as compared to
PFV. Alternatively, an HIV-1 IN residue that is function-
ally analogous to Arg329 in PFV IN exists, but it was
overlooked in this study. As Arg231 mutants were select-
ively defective for DNA strand transfer activity (Figure 2)
and exhibited altered overall nucleotide and RY dinucleo-
tide preferences during integration (Figures 4, 7 and
Supplementary Figure S2), we nevertheless conclude it is
likely to play a role in tDNA distortion. Due to the dif-
ferent lengths of HIV-1 and PFV CTD b1-b2 loop regions,
residues abutting Arg231 in HIV-1 IN, including Asp229,
Ser230 and Asn232, were mutagenized (Figure 1B). The
in vitro nucleotide site preferences of S230N and N232R
mutant INs did not vary from the WT, indicating that
neither of these residues is likely to contact tDNA bases
during integration. The virtual lack of D229R IN con-
certed integration activity precluded its site analysis.
A model for the HIV-1 TCC was built by overlying our
previous HIV-1 IN-vDNA intasome model with the PFV
TCC structure to further investigate the functionality of
CTD arginine residues. Arg231 in HIV-1 IN expectedly
aligned with PFV IN residue Arg329 in the model
(Supplementary Figure 6A). Our intasome model was
assembled step-wise from separate HIV-1 IN 2-domain
structures, and the Arg231 side chain in the model and
the 2-domain CCD–CTD structure on which it was built
(55) positions away from the tDNA. Superposition of two
available CTD NMR structures (54,56) revealed consider-
able ﬂexibility among Arg231 side chain positions
(Supplementary Figure S6A), indicating that Arg231 is in
theory positioned to interact with tDNA during HIV-1
integration. Arg228, the nearest arginine to Arg231 in the
primary HIV-1 IN sequence (Figure 1B), in contrast
aligned with vDNA (Supplementary Figure 6B) (27).
We note that one HIV-1 intasome model, in particular,
yielded a shift in the register of CTD b strands, such that
residues E246GAVVIQ situated between b1 and b2 (57). It
could be informative to assess integration site preferences
of IN mutant enzymes containing changes of some of
these residues.
CONCLUSIONS
Although we did not assess the IN–DNA-binding
afﬁnities of mutant enzymes in this study, we expect
such measures would in the majority of cases be unin-
formative. The S124D mutation, which abrogated RSV
IN strand transfer activity, instilled a relatively mild
2-fold defect in sequence non-speciﬁc DNA binding (47).
We accordingly suspect that S119A and S119T mutant
enzymes, which retained >50% of strand-transfer
activity and showed the greatest variation among
integration site sequence preferences, would support
normal levels of tDNA binding under similar reaction
conditions.
Numerous factors likely contribute to the subtle differ-
ences observed between in vitro and virus-derived integra-
tion-site datasets (compare Figures 4 and 7). As
mentioned above, direct sequencing of only one of two
viral-cellular DNA joints distorted palindromic
symmetry, a trend that is largely overcome by analyzing
several thousands of integration sites (20,58). Inherent dif-
ferences between the in vitro and live cell tDNA template
also likely inﬂuenced the outcome. Whereas puriﬁed
LEDGF/p75 protein binds DNA in a sequence non-
speciﬁc manner (59), chromatin binding is accomplished
through the additional engagement of trimethylated Lys36
on histone H3 (H3K36me3) (60,61), an epigenetic mark
that typically associates with actively transcribed genes
(reviewed in 62). Biochemical reactions that utilized nu-
cleosomes as the source of tDNA ﬁrst established the pref-
erence of HIV-1 IN for tDNA distortion (63,64).
LEDGF/p75 accordingly targets integration to distorted
nucleosomal DNA that exists in cells in an inherently dif-
ferent structural conformation than the naked plasmid
DNA used in our in vitro reactions. DNA remodeling
enzymes and members of the RNA polymerase transcrip-
tion machinery that associate with H3K36me3 chromatin
may also contribute to tDNA distortion at sites of inte-
gration. Despite these limitations, similarly skewed tDNA
nucleotide preferences among the subset of IN mutants
that were studied as puriﬁed enzymes and viruses
(Figures 4 and 7) indicate that IN is the primary deter-
minant responsible for nucleotide selection at sites of
vDNA integration.
The work presented here importantly uncovers the
mechanistic basis for tDNA distortion during HIV-1 inte-
gration. First, we clarify that distortion is spread over two
inherently ﬂexible dinucleotides (at positions 1 and 2, and
at positions 2 and 3), which contrasts with the distortion
of a single, central dinucleotide during PFV integration.
The spreading of tDNA distortion over two dinucleotides
is likely to put less overall strain on the DNA molecule; in
this vein it is not surprising that we did not pinpoint a
single amino acid, similar to Arg329 in PFV IN, that
contributed signiﬁcantly to alleviating the penalty of
tDNA distortion. Our results moreover clarify that retro-
viral IN residues analogous to Ala188 in PFV and Ser119
in HIV-1 interact with bases at three positions upstream
and downstream from the sites of vDNA joining to help
impart the tDNA distortion necessary for concerted
vDNA integration.
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